Activating Signal Cointegrator 1 Complex Protein: A Potential Drug Target and Biomarker

Target Name: Activating signal cointegrator 1 complex protein

NCBI ID: P15280

Activating signal cointegrator 1 complex protein

Other Name(s): None

Activating Signal Cointegrator 1 Complex Protein: A Potential Drug Target and Biomarker

Signal cointegrator 1 (SCL/TAL1) is a non-coding RNA-protein hybrid that plays a crucial role in the regulation of cell growth, differentiation, and survival. The SCL/TAL1 complex is a highly conserved protein complex that is involved in various cellular processes, including cell signaling, DNA replication, and repair. The complex consists of various proteins that work together to ensure the stability and activation of SCL/TAL1, including cointegrator 1 (C1), cointegrator 2 (C2), and cointegrator 3 (C3).

The SCL/TAL1 complex has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting the SCL/TAL1 complex using drugs or other therapeutic approaches has become an attractive strategy for the development of new treatments.

In this article, we will discuss the Activating Signal Cointegrator 1 complex protein, including its structure, function, and potential as a drug target or biomarker.

Structure and Function

The SCL/TAL1 complex is a protein complex that consists of four subunits: SCL/TAL1 (19kDa), cointegrator 1 (C1, 11kDa), cointegrator 2 (C2, 11kDa), and cointegrator 3 (C3, 16kDa). The SCL/TAL1 complex has a characteristic hour-long dimerization process, which is regulated by the cointegrator 2 (C2) protein.

The SCL/TAL1 complex plays a vital role in the regulation of cellular processes, including cell growth, differentiation, and apoptosis. One of the critical functions of the SCL/TAL1 complex is the regulation of cell signaling pathways. The complex interacts with various signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

The SCL/TAL1 complex is also involved in the regulation of DNA replication and repair. The complex interacts with the microtubule protein TP100 and the chromatin protein H11. These interactions ensure the proper organization and regulation of the DNA replication machinery.

The SCL/TAL1 complex is also involved in the regulation of cellular stress responses. The complex interacts with the protein heat shock protein HSP70 and the transcription factor p21. These interactions help to ensure the proper regulation of cellular stress responses and the maintenance of cellular homeostasis.

Potential as a Drug Target

The SCL/TAL1 complex has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting the SCL/TAL1 complex using drugs or other therapeutic approaches has become an attractive strategy for the development of new treatments.

One of the potential drug targets for the SCL/TAL1 complex is the inhibition of the activity of cointegrator 2 (C2). C2 is a key protein that regulates the SCL/TAL1 complex and is involved in the regulation of cellular processes, including cell growth, differentiation, and apoptosis. The inhibition of C2 activity has been shown to have therapeutic effects in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another potential drug target for the SCL/TAL1 complex is the targeting of cointegrator 3 (C3). C3 is the last protein in the SCL/TAL1 complex and is involved in

Protein Name: Activating Signal Cointegrator 1 Complex Protein

The "Activating signal cointegrator 1 complex protein Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Activating signal cointegrator 1 complex protein comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets